Hildred, Bourne and Emerson Group establish Carlin Consumer Health business
Healthcare private equity firms Hildred Capital Management, Bourne Partners Strategic Capital and the Emerson Group have joined forces to launch a new consumer health business.
The brainchild from the three companies is Carlin Consumer Health, a consumer health business that has been established to acquire over-the-counter brands, the companies said.
[Read More: Dr. Reddy’s intros OTC naproxen sodium tablets]
“As the OTC market continues to grow rapidly and large pharmaceutical companies look to divest one-off consumer brands, we see a number of compelling investment opportunities for firms with the healthcare experience, industry relationships and operational know-how needed to drive growth,” Andrew Goldman, the managing partner of Hildred said. “We believe our firms’ collective expertise and track record for building similar platforms, such as Crown Laboratories, Inc. and Covis Pharma, position Carlin extremely well to drive substantial value creation for all stakeholders.”
Carlin will be positioned to acquire and commercialize well-established brands and support its retail partners and their customers, the companies said.
As a way to kick off this news, Carlin announced its first acquisition — Zegerid OTC from Bayer AG.
[Read More: Alcon extends Systane Lubricant Eye Drop availability]
“We are excited to collaborate with Hildred and Emerson to build a platform of strategically-aligned brands that can benefit from our operationally-focused strategy and collaborative approach to partnering with retailers to meet the health and wellness needs of consumers and their families,” Minor Hinson, the chief investment officer of Bourne said. “We look forward to transitioning Zegerid to Carlin and pursuing additional attractive opportunities in our pipeline.”
Zegerid is an OTC proton pump inhibitor that is used for the treatment of frequent heartburn with a unique dual-ingredient brand combination that provides up to 24-hour relief via one capsule.
[Read More: Over the moon for OTC: Several trends are converging and pushing sales up]
“With market-leading consumer loyalty and significant potential for growth through investments in sales, marketing and product development, Zegerid is a terrific first asset for Carlin,” said Scott Emerson, CEO of The Emerson Group. “As a well-capitalized platform with shareholders that maintain longstanding industry relationships, Carlin is uniquely positioned in this space, and we look forward to building out our platform with additional accretive acquisitions.”